echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Metabolomic analysis reveals a key weakness in neuroblastoma: dependence on fatty acids for survival

    Metabolomic analysis reveals a key weakness in neuroblastoma: dependence on fatty acids for survival

    • Last Update: 2022-10-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The researchers were able to reduce the growth
    of MYCN-amplified tumors.


    "Treating neuroblastoma directly against MYCN is challenging," said
    Eveline Barbieri, Ph.


    Barbieri and her colleagues compared the metabolic profiles
    of MYCN-ampened neuroblastomas with non-MYCN-amplified neuroblastomas using unbiased metabolomic analysis.


    Barbieri said: "We found that the amplification of MYCN recombins the lipid metabolism of tumors, promoting the use and biosynthesis of fatty acids, a type
    of lipid that lipid cells can use as a source of energy.


    Barbieri and her colleagues propose that MYCN changes the route of lipid metabolism to make it easier for fatty acids to enter cancer cells, thereby promoting the growth
    of tumor cells.


    Study its mechanism

    Barbieri said: "When we looked at what prompted MYCN-amplified neuroblastomas to grow fatty acid-dependent growth, we found that MYCN directly upregulates or enhances the production of fatty acid transporter 2 (FATP2), the molecule
    that mediates cellular absorption of fatty acids.


    When the researchers neutralized the activity of FATP2 by knocking out the gene or blocking the action of FATP2 with a small molecule inhibitor, they reduced the growth
    of MYCN-amplified tumors.


    Barbieri said: "We observed that when we block fatty acids from entering cancer cells, the growth of tumor cells decreases
    .


    There are other MYCN-amplified childhood and adult tumors
    .


    These findings suggest that therapeutic interventions that interfere with FATP2 activity may selectively block fatty acid uptake by MYCN-ampampled tumors, stopping or reducing tumor growth, making it more sensitive
    to conventional chemotherapy.


    Barbieri said: "More needs
    to be done before this approach can be applied to the clinic.


    MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma


                  

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.